Annexon, Inc.
NASDAQ: ANNX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Douglas E. Love
- Employees
- 106
- Headquarters
- Brisbane, United States
- IPO year
- 2020
- Market cap
- $633.9M
- Website
- https://www.annexonbio.com
Loading ANNX…
Loading profile data…Frequently asked questions about ANNX
What does Annexon, Inc. (ANNX) do?
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to ad...
Where does ANNX trade?
Annexon, Inc. (ANNX) trades on the NASDAQ Global Select.
What sector is ANNX in?
Annexon, Inc. (ANNX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Annexon, Inc.?
Douglas E. Love is the chief executive officer of Annexon, Inc. (ANNX).
Where is Annexon, Inc. headquartered?
Annexon, Inc. is headquartered in United States.
Does ANNX pay a dividend?
Annexon, Inc. (ANNX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ANNX go public?
Annexon, Inc. (ANNX) completed its initial public offering in 2020.